Therapeutic Response

v::ALK status confers therapeutic sensitivity to Brigatinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Alunbrig (brigatinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized brigatinib as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who were previously not treated with an ALK inhibitor.
Alunbrig (brigatinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized brigatinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
Alunbrig (brigatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to brigatinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.
Brigatinib Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved brigatinib for reimbursement as a treatment option for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib, and whose ALK rearrangement has been demonstrated by an accurate and validated test method.
Brigatinib Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved brigatinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor, and whose ALK rearrangement has been demonstrated by an accurate and validated test method.